Resource Library

Technology alone won't get you where you want to go. And that's why we won't ever just offer technology.

Filter by

Resource type

Application Note
Brochure
Primary Literature
Scientific Brief
Scientific Poster
Webinar/Presentation

Application

Cell Therapy
CRISPR/Gene Editing
Cell Based Assays
Viral Vectors
Vaccines
Protein Production
Stem Cells
Cell Line Development

Cell type

Dendritic Cells
ESC
Neurons
Insect Cell Lines (S2/Sf9/Sf21)
Keratinocytes
HEK293
Cancer Cell Lines
CHO
iPSCs
Cardiomyocytes
NPCs/NSCs
B Cells
NK Cells
Fibroblasts
MSCs
PBMCs
HSPCs
T Cells
Other Mammalian Cell Lines

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

HSPCs

Ex Vivo Gene Correction in X-CGD Patient Stem Cells

Clinically-relevant Levels of gp91+ Cells in the Peripheral Blood and Bone Marrow Following Engraftment.

Scientific Brief

CRISPR/Gene Editing

Primary Cells

TCR/CAR T

Gene Editing

MaxCyte Enables Delivery of Transposons for Highly-Efficient CAR T Cell Engineering

Chimeric antigen receptors (CAR) T cells are a revolutionary approach to enhancing the body’s natural anti-cancer immune responses and have shown the best efficacy in clinical trials as adoptive cell therapies for treating hematological malignancies. However, excitement surrounding this sophisticated therapy has been tempered by complications including T cell exhaustion, limited efficacy in solid tumors, and the cost and complexity of manufacturing.

Scientific Brief

Protein Production

CHO

MaxCyte® Electroporation Enabled Immunocytokine Development

Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive tissue inflammation, uncontrolled antibody production and an imbalance of immunoregulatory cytokines.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

T Cells

Electroporation of a Non-Integrative DNA Nanovector for Efficient, Semi-Automated, GMP Manufacturing of CAR T Cell Therapies

Chimeric Antigen Receptors (CARs) have shown extraordinary efficacy in numerous clinical trials as an adoptive cell therapy to treat hematological malignancies. Still, CAR T therapy faces significant challenges, ranging from long lead times and expensive manufacturing to complicated vector engineering.

Scientific Brief

Protein Production

CHO

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry

Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies.

Scientific Brief

Viral Vectors

Vaccines

MaxCyte® Enabled Innovative SARS-CoV-2 Vaccine Development

The pandemic caused by SARS-CoV-2 has killed millions worldwide and remains an incredible burden to global health care systems. Although vaccines have proven effective at preventing COVID-19-related mortality, they do not generate sterilizing immunity.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

Gene Therapy

iPSCs

Highly Efficient Homozygous Correction of the DYSF Gene in Miyoshi Myopathy Patient iPSCs by ssODN-Mediated Knockin

Human induced pluripotent stem cells (iPSCs) play an important role in disease modeling and drug screening, and have tremendous potential for regenerative medicine.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

Gene Therapy

iPSCs

NK Cells

Generation of Heterozygous HLA-C iPSCs by ssODN Electroporation for Allogeneic Transplantation

Human-induced pluripotent stem cells (iPSCs) have tremendous potential for regenerative medicine. While there is an ongoing effort to recruit human leukocyte antigen (HLA) homozygous donors for allogeneic transplantation, a significant challenge with this approach is the susceptibility of these cells to host natural killer (NK) cell cytotoxicity.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

PBMCs

T Cells

Advancing an HIV Clinical Program for CCR5 Gene Disruption

Precision genome engineering requires technologies that allow efficient and reproducible delivery of DNA, mRNA and RNP-based reagents into a range of primary cells and stem cells. In addition, clinical gene editing requires a transfection platform that is GMP-compliant and scalable to accom- modate billions of cells in a single transfection.

Scientific Brief

Cell Therapy

CRISPR/Gene Editing

iPSCs

Gene Knockin via Homology-directed Repair in Human iPSCs

Clinically validated and scalable MaxCyte® Flow Electroporation® Technology delivered ribonucleoprotein (RNP) and single-stranded oligonucleotide donor (ssODN) to induced pluripotent stem cells (iPSCs).

Peer Reviewed Publications Featuring MaxCyte Electroporation

View Publications

Featured Science

View Featured Science

Resource Library

Filter by

Resource type

Application

Cell type

Ex Vivo Gene Correction in X-CGD Patient Stem Cells

MaxCyte Enables Delivery of Transposons for Highly-Efficient CAR T Cell Engineering

MaxCyte® Electroporation Enabled Immunocytokine Development

Electroporation of a Non-Integrative DNA Nanovector for Efficient, Semi-Automated, GMP Manufacturing of CAR T Cell Therapies

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry

MaxCyte® Enabled Innovative SARS-CoV-2 Vaccine Development

Highly Efficient Homozygous Correction of the DYSF Gene in Miyoshi Myopathy Patient iPSCs by ssODN-Mediated Knockin

Generation of Heterozygous HLA-C iPSCs by ssODN Electroporation for Allogeneic Transplantation

Advancing an HIV Clinical Program for CCR5 Gene Disruption

Gene Knockin via Homology-directed Repair in Human iPSCs

Peer Reviewed Publications Featuring MaxCyte Electroporation

Featured Science

Receive upcoming events, new resources and more in your inbox